What is Bot MD?
Founded in 2018 and headquartered in Anaheim, California, Bot MD operates as a specialized platform designed to empower healthcare professionals with instantaneous access to critical clinical information. The company addresses the persistent challenge of information fragmentation in medical environments by providing a secure, intuitive interface for practitioners to retrieve data and facilitate seamless communication regarding patient updates. By integrating directly into the clinical workflow, Bot MD serves as a vital digital assistant, reducing administrative burden and allowing medical teams to focus on high-acuity patient care. Its market position is defined by its ability to synthesize vast amounts of medical literature and institutional protocols into actionable insights, effectively serving as a force multiplier for hospital staff and clinical departments.
How much funding has Bot MD raised?
Bot MD has raised a total of $5M across 1 funding round:
Series A
$5M
Series A (2021): $5M with participation from Yoh-Chie Lu, Steve Blank, SeaX, Jean-Luc Butel, XA Network, Monk’s Hill Ventures, and SGInnovate
Key Investors in Bot MD
Steve Blank
A renowned expert in innovation and entrepreneurship, providing methodologies for startups and organizations to navigate complex market landscapes through lean startup principles.
SGInnovate
A Singapore-based investment firm focused on cultivating the Deep Tech ecosystem by supporting startups and fostering talent in emerging technology sectors.
Monk’s Hill Ventures
A venture capital firm specializing in early-to-growth stage technology companies, with a strong emphasis on supporting high-potential startups across Southeast Asia.
What's next for Bot MD?
Looking ahead, the strategic deployment of this $5M will likely focus on deepening the platform's integration capabilities and expanding its reach into new clinical specialties. As the company transitions from its initial growth phase into a more mature enterprise-level operation, the focus will shift toward enhancing the robustness of its AI models and ensuring compliance with evolving global healthcare data standards. The backing from high-profile investors suggests a long-term commitment to scaling the platform's infrastructure, potentially paving the way for international market entry and the development of advanced predictive analytics features that could redefine standard operating procedures in modern healthcare facilities.
See full Bot MD company page
